The Oral JAK/SYK Inhibitor ASN002 Demonstrates Efficacy and Improves Associated Systemic Inflammation in Patients with Moderate-to-Severe Atopic Dermatitis: Results from a Randomised, Double-Blind, Placebo-Controlled Study.

R Bissonnette,C Maari,S Forman,N Bhatia, M Lee,J Fowler,S Tyring,D Pariser,H Sofen,S Dhawan,M Zook,D J Zammit,H Usansky,L Denis,N Rao,T Song,A B Pavel,E Guttman-Yassky

BRITISH JOURNAL OF DERMATOLOGY（2019）

引用 83|浏览37

暂无评分

关键词

JAK , SYK ,ASN002,Atopic dermatitis,JAK inhibitor,SYK inhibitor,immune response,randomised controlled trial,systemic inflammation,treatment outcome,tyrosine kinases

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要